The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats

International Journal of Pharmaceutics

Volumn 379, Issue 1-2, 2009, Pages 100-108

  Hamid, Khuriah Abdul ^a,b   Katsumi, Hidemasa ^a   Sakane, Toshiyasu ^a   Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Intestinal absorption; Intestinal transport; Low water soluble drug; Membrane toxicity; Pharmaceutical excipient; Solubilizing agent

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 6 CARBOXYFLUORESCEIN; ALCOHOL; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; DIMETHYL SULFOXIDE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GELUCIRE; LABRASOL; LACTATE DEHYDROGENASE; MACROGOL 400; POLYSORBATE 80; PROPYLENE GLYCOL; RICINOMACROGOL; SOLUBILIZER; TAUROCHOLIC ACID;

ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DIFFUSION CHAMBER; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MALE; MEMBRANE DAMAGE; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SOLUBILITY;

ANIMALS; BIOLOGICAL AVAILABILITY; DEXTRANS; EXCIPIENTS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCEINS; INTESTINAL ABSORPTION; JEJUNUM; L-LACTATE DEHYDROGENASE; MALE; RATS; RATS, WISTAR; SOLUBILITY; TOXICITY TESTS;

EID: 68649091177     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.06.018     Document Type: Article

References (43)

1. Dahan A., and Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Control Release 129 (2008) 1-10
2. David N.A. The pharmacology of dimethyl sulfoxide. Ann. Rev. Pharmacol. 12 (1972) 353-374
3. Davis W.W., Pfeiffer R.R., and Quay J.F. Normal and promoted gastrointestinal absorption of water-soluble substances. I. Induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch. J. Pharm. Sci. 59 (1970) 960-963
4. Eaimtrakarn S., Rama Prasad Y.V., Ohno T., Konishi T., Yoshikawa Y., Shibata N., and Takada K. Absorption enhancing effect of Labrasol on the intestinal absorption of insulin in rats. J. Drug Target. 10 (2002) 255-260
5. Fernandez S., Jannin V., Rodier J.D., Ritter N., Mahler B., and Carriere F. Comparative study on digestive lipase activities on the self emulsifying excipient labrasol, medium chain glycerides and PEG esters. Biochim. Biophys. Acta 1771 (2007) 633-640
6. 1,7]-eel calcitonin in rats. J. Control Release 106 (2005) 287-297
7. Gao Y., He L., Katsumi H., Sakane T., Fujita T., and Yamamoto A. Improvement of intestinal absorption of water-soluble macromolecules by various polyamines: intestinal mucosal toxicity and absorption-enhancing mechanism of spermine. Int. J. Pharm. 354 (2008) 126-134
8. Gao Y., He L., Katsumi H., Sakane T., Fujita T., and Yamamoto A. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int. J. Pharm. 359 (2008) 70-78
9. Gizurarson, S., 1990. Intranasal application of insulin. Doctoral Dissertation, the Royal Danish School of Pharmacy, Copenhagen, Denmark.
10. Gotoh S., Nakamura R., Nishiyama M., Quan Y.S., Fujita T., Yamamoto A., and Muranishi S. Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine. J. Pharm. Sci. 85 (1996) 858-862
11. Grass G.M., and Sweetana S.A. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res. 5 (1988) 372-376
12. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. J. Pharm. Toxicol. Method 56 (2007) 145-158
13. Hu Z., Tawa R., Konishi T., Shibata N., and Takada K. A novel emulsifier, labrasol, enhances gastrointestinal absorption of gentamicin. Life Sci. 69 (2001) 2899-2910
14. Johansson F., Hjertberg E., Eirefelt S., Tronde A., and Bengtsson U.H. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17 (2002) 63-71
15. Johnson B.M., Charman W.N., and Porter C.H. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and Vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm. Sci. 4 (2002) E40
16. Kawakami K., Miyoshi K., and Ida Y. Solubilization behaviour of poorly soluble drugs with combined use of gelucire 44/14 and cosolvent. J. Pharm. Sci. 93 (2004) 1471-1479
17. Legen I., Kracun M., Salobir M., and Kerc J. The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. Int. J. Pharm. 308 (2006) 84-89
18. Lin J.H., Chen I.-W., and deLuna F.A. On the absorption of alendronate in rats. J. Pharm. Sci. 83 (1994) 1741-1746
19. Lin Y., Shen Q., Katsumi H., Okada N., Fujita T., Jiang X., and Yamamoto A. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine 123, a P-glycoprotein substrate, in rats. Biol. Pharm. Bull. 30 (2007) 1301-1307
20. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
21. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7 (1990) 1-33
22. Oda M., Saitoh H., Kobayashi M., and Aungst B.J. β-Cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int. J. Pharm. 280 (2004) 95-102
23. Rama Prasad Y.V., Puthli S.P., Eaimtrakarn S., Ishida M., Yoshikawa Y., Shibata N., and Takada K. Enhanced intestinal absorption of vancomycin with Labrasol and d-α-tocopheryl PEG 1000 succinate in rats. Int. J. Pharm. 250 (2003) 181-190
24. Rege B.D., Yu L., Hussain A.S., and Polli J.E. Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci. 90 (2001) 1776-1786
25. Sachs-Barrable K., Thamboo A., Lee S.D., and Wasan K.M. Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 10 (2007) 319-331
26. Sakai M., Imai T., Ohtake H., Azuma H., and Otagiri M. Effects of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J. Pharm. Sci. 86 (1997) 779-785
27. Shah V.P., Yacobi A., Barr W.H., Benet L.Z., Breimer D., Dobrinska M.R., Endrenyi L., Fairweather W., Gillespie W., Gonzalez M.A., Hooper J., Jackson A., Lesko L.J., Midha K.K., Noonan P.K., Petnaik R., and Williams R.L. Workshop report: evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res. 13 (1996) 1590-1594
28. Shen Q., Lin Y., Handa T., Doi M., Sugie M., Wakayama K., Okada N., Fujita T., and Yamamoto A. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 313 (2006) 49-56
29. Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., and Yamamoto A. Modulation of intestinal P-glycoprotein function by Cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93 (2004) 877-885
30. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21 (2004) 201-230
31. Sugiyama T., Yamamoto A., Kawabe Y., Uchiyama T., Quan Y.-S., and Muranishi S. Effects of various absorption enhancers on the intestinal absorption of water soluble drugs by in vitro Ussing chamber method: correlation with an in situ absorption experiment. Biol. Pharm. Bull. 20 (1997) 812-814
32. Takahashi Y., Kondo H., Yasuda T., Watanabe T., Kobayashi S., and Yokohama S. Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs. Int. J. Pharm. 246 (2002) 85-94
33. Totterman A.M., Schipper N.G., Thompson D.O., and Mannermaa J.-P. Intestinal safety of water soluble β-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol. 49 (1997) 43-48
34. Uchiyama T., Yamamoto A., Hatano H., Fujita T., and Muranishi S. Effectiveness and toxicity screening of various absorption enhancers in the large intestine: intestinal absorption of phenol red and protein and phospholipid release from the intestinal membrane. Biol. Pharm. Bull. 19 (1996) 1618-1621
35. Uchiyama T., Sugiyama T., Quan Y.-S., Kotani A., Okada N., Fujita T., Muranishi S., and Yamamoto A. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption enhancing mechanism of n-lauryl-β-d-maltopyranoside. J. Pharm. Pharmacol. 51 (1999) 1241-1250
36. Wang L., Jiang X., Xu W., and Li C. Complexation of tanshinone IIA with 2-hydroxypropyl-β-cyclodextrin: effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats. Int. J. Pharm. 341 (2007) 58-67
37. Yamamoto A., Hayakawa E., Kato Y., Nishiura A., and Lee V.H.L. A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J. Pharmacol. Exp. Ther. 263 (1992) 25-31
38. Yamamoto A., Taniguchi T., Rikyuu K., Tsuji T., Fujita T., Murakami M., and Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 (1994) 1496-1500
39. Yamamoto A., Uchiyama T., Nishikawa R., Fujita T., and Muranishi S. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J. Pharm. Pharmacol. 48 (1996) 1285-1289
40. Yamamoto A., Okagawa T., Kotani A., Uchiyama T., Shimura T., Tabata S., Kondo S., and Muranishi S. Effects of different absorption enhancers on the permeation of ebiratide, an ACTH analogue, across intestinal membranes. J. Pharm. Pharmacol. 49 (1997) 1057-1061
41. Yamamoto A., Tatsumi H., Maruyama M., Uchiyama T., Okada N., and Fujita T. Modulation of intestinal permeability by nitric oxide donors: implications in intestinal delivery of poorly absorbable drugs. J. Pharmacol. Exp. Ther. 296 (2001) 84-90
42. 1,7]-eel calcitonin from various mucosal administration sites. J. Control Release 76 (2001) 363-374
43. Zerrouk N., Corti G., Ancillotti S., Maestrelli F., Cirri M., and Mura P. Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability. Eur. J. Pharm. Biopharm. 62 (2006) 241-246